S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
OTCMKTS:PTIX

Protagenic Therapeutics Stock Forecast, Price & News

$6.51
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.51
Now: $6.51
$6.51
50-Day Range
$2.44
MA: $4.28
$7.00
52-Week Range
$0.16
Now: $6.51
$7.00
Volume7 shs
Average Volume771 shs
Market Capitalization$67.44 million
P/E RatioN/A
Dividend YieldN/A
Beta-4.05
Protagenic Therapeutics, Inc. engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PTIX
CUSIPN/A
Phone212-994-8200
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share

Profitability

Net Income$-1,750,000.00

Miscellaneous

Market Cap$67.44 million
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.65 out of 5 stars

Medical Sector

1283rd out of 1,969 stocks

Business Services, Not Elsewhere Classified Industry

119th out of 192 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$6.51
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PTIX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions

What stocks does MarketBeat like better than Protagenic Therapeutics?

Wall Street analysts have given Protagenic Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Protagenic Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Protagenic Therapeutics' next earnings date?

Protagenic Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Protagenic Therapeutics
.

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) released its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.06) earnings per share for the quarter.
View Protagenic Therapeutics' earnings history
.

How has Protagenic Therapeutics' stock price been impacted by Coronavirus?

Protagenic Therapeutics' stock was trading at $1.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PTIX shares have increased by 282.9% and is now trading at $6.51.
View which stocks have been most impacted by COVID-19
.

Who are Protagenic Therapeutics' key executives?

Protagenic Therapeutics' management team includes the following people:
  • Dr. Garo H. Armen, Co-Founder & Exec. Chairman (Age 68)
  • Dr. Alexander Kenneth Arrow C.F.A., M.D., CFA, CFO & Sec. (Age 50, Pay $9.09k)
  • Dr. David A. Lovejoy, Scientific Founder
  • Mr. Andrew Slee, Chief Operating Officer
  • Dr. Dalia Barsyte, Chief Technology Advisor
  • Dr. Robert Benjamin Stein, Chief Medical Officer & Director (Age 70)

Who are some of Protagenic Therapeutics' key competitors?

What other stocks do shareholders of Protagenic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagenic Therapeutics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), (PCSA), Acasti Pharma (ACST), Akero Therapeutics (AKRO), Athersys (ATHX), AVEO Pharmaceuticals (AVEO), CymaBay Therapeutics (CBAY), Cerecor (CERC) and Cumberland Pharmaceuticals (CPIX).

What is Protagenic Therapeutics' stock symbol?

Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."

How do I buy shares of Protagenic Therapeutics?

Shares of PTIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagenic Therapeutics' stock price today?

One share of PTIX stock can currently be purchased for approximately $6.51.

How much money does Protagenic Therapeutics make?

Protagenic Therapeutics has a market capitalization of $67.44 million.

What is Protagenic Therapeutics' official website?

The official website for Protagenic Therapeutics is www.protagenic.com.

Where are Protagenic Therapeutics' headquarters?

Protagenic Therapeutics is headquartered at 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010.

How can I contact Protagenic Therapeutics?

Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at 212-994-8200 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.